Short selling is one of the most transparent forms of market pessimism available.
When professional investors bet against a stock, they not only demonstrate their conviction but also send a signal to the market.
This week, three well-known ASX shares are attracting significant short interest.
Should investors be worried?
Image source: Getty Images
WiseTech Global Ltd (ASX: WTC)
WiseTech is down 43% year to date and 63% over the past twelve months.
The short sellers who have been betting against WiseTech shares have been richly rewarded in 2026.
According to the latest ASIC short position data, 7.93% of WiseTech shares are currently held as short positions, placing it among the more heavily shorted stocks in the ASX technology sector.
The bear case rests on three pillars.
First, the company announced it would cut approximately 2,000 jobs as part of a two-year AI-linked restructuring program, nearly a third of its total workforce, attracting union intervention and a Fair Work Commission claim.
Second, the Q3 FY2026 update confirmed that one-off integration costs related to the E2open acquisition would reach US$45 million to US$50 million in FY2026, materially compressing profit margins.
Third, analysts have cut the consensus full-year FY2026 EPS forecast as earnings forecasts have been revised downward following the integration cost blowout.
However, there is also a credible counter-argument in favour of WiseTech.
WiseTech's CargoWise platform is used by all of the world's top 25 global freight forwarders. The platform has high switching costs, giving strong future revenue visibility.
Bell Potter sees strong upside from current levels, and the business model continues to generate strong recurring revenue despite the near-term headwinds.
The bears may be right in the short term, but the long-term case is considerably harder to dismiss.
Cochlear Ltd (ASX: COH)
Cochlear shares are down 61% year to date, making the company one of the worst-performing large-cap ASX stocks in 2026.
The short sellers targeting Cochlear are betting that the April earnings downgrade marks the beginning of a more sustained deterioration. Today, 4.7% of outstanding shares are reported as being held short.
Their case rests on two concerns.
First, the 30% guidance cut was driven partly by hospital capacity constraints and declining hearing aid referrals in developed markets, trends that could persist for several quarters.
Second, Morgans retained a hold rating and cut its price target to $107.17, while Macquarie slashed its target from $239 to $115, signalling genuine broker uncertainty about the recovery timeline.
Nevertheless, the bull case must also be considered.
Cochlear holds approximately 50% global market share in a market with just 3% penetration of an addressable patient population exceeding six million people in developed markets alone.
Jarden sees significant upside from current levels, and CEO Dig Howitt has been clear that surgeries are being delayed, not cancelled. He points specifically to short-term disruptors such as the conflict in the Middle East as an explanation for this trend.
Lendlease Group (ASX: LLC)
Lendlease shares crashed 6% yesterday after the company announced the sale of its Milano Santa Giulia development rights for $250 million. This translated into the booking of a $175 million post-tax operating loss.
The stock is down 55% over the past twelve months.
The short sellers (6.37% of total shares) have the most straightforward case of the three.
Lendlease is selling assets at material discounts to book value, recognising significant losses in the process. This raises questions about whether the remaining portfolio is also overvalued on the balance sheet.
Furthermore, each divestment removes future earnings potential, making it harder to see how the business rebuilds to a meaningfully larger earnings base in the medium term.
However, Lendlease management pointed to more than three billion dollars in liquidity and a Moody's investment grade credit rating, arguing the balance sheet can absorb the losses while the simplification strategy plays out.
Foolish takeaway
Short sellers are sometimes right, but they are rarely right forever.
WiseTech, Cochlear, and Lendlease each face real near-term challenges that justify some level of caution.
However, all three also carry longer-term qualities that suggest the current pessimism may be creating opportunities for patient investors willing to accept short-term volatility.
